发布求助
文献互助 智能选刊 最新文献

Drug Discovery Today最新文献

筛选
英文 中文
Promoting the social implementation of digital and mobile health: effects of regulation on user and non-user behavior in East Asia 促进数字和移动医疗的社会实施：监管对东亚用户和非用户行为的影响。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-06 DOI: 10.1016/j.drudis.2024.104136
Hanlin Feng , Makoto Niwa , Jianfei Cao , Karin Kurata , Shuo Zhang , Yenogjoo Lim , Tack Joong Kim , Xitong Guo , Itsuki Kageyama , Kota Kodama
{"title":"Promoting the social implementation of digital and mobile health: effects of regulation on user and non-user behavior in East Asia","authors":"Hanlin Feng ,&nbsp;Makoto Niwa ,&nbsp;Jianfei Cao ,&nbsp;Karin Kurata ,&nbsp;Shuo Zhang ,&nbsp;Yenogjoo Lim ,&nbsp;Tack Joong Kim ,&nbsp;Xitong Guo ,&nbsp;Itsuki Kageyama ,&nbsp;Kota Kodama","doi":"10.1016/j.drudis.2024.104136","DOIUrl":"10.1016/j.drudis.2024.104136","url":null,"abstract":"<div><p>This study conducted policy and regulation analyses and user acceptance surveys in three East Asian countries with developed telecommunication infrastructure (China, South Korea, and Japan) to determine the most effective way to implement mobile health (mHealth). Regional differences in users’ emphasis on the purpose of mHealth, including medical information referral or health management, appear to be influenced by regional regulation, thus making regulation analysis important when considering mHealth penetration strategies. Potential mHealth users have high expectations for medical information and correspondence, which is crucial for the pharmaceutical industry in terms of providing information and retaining patients. Furthermore, potential users are willing to use the system medically, which is beneficial to the pharmaceutical industry when introducing mHealth and prescriptions in combination.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 10","pages":"Article 104136"},"PeriodicalIF":6.5,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002617/pdfft?md5=9f4bb18440e57af47ac64b4282921428&pid=1-s2.0-S1359644624002617-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141905296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023) 20 强制药公司获得 FDA 批准情况的比较分析（2014-2023 年）。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-05 DOI: 10.1016/j.drudis.2024.104128
Alexander Schuhmacher , Oliver Gassmann , Markus Hinder , Dominik Hartl
{"title":"Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)","authors":"Alexander Schuhmacher ,&nbsp;Oliver Gassmann ,&nbsp;Markus Hinder ,&nbsp;Dominik Hartl","doi":"10.1016/j.drudis.2024.104128","DOIUrl":"10.1016/j.drudis.2024.104128","url":null,"abstract":"<div><p>This article addresses the research and development (R&amp;D) productivity challenge of the pharmaceutical industry, focusing on United States Food and Drug Administration (FDA)-related new drug approvals of the top 20 pharmaceutical companies (2014–2023). We evaluated the degree of innovation in new drugs to determine the innovativeness of these leading companies. A key finding of our analysis is the decline in the number of new drugs approved by the FDA for these leading companies over the investigated time period. This trend suggests that some of the leading companies are losing ground in R&amp;D innovation, raising concerns about their ability to sustain competitive advantage, ensure long-term market success, and maintain viable business models.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104128"},"PeriodicalIF":6.5,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002538/pdfft?md5=41432e6fdcef9771d76b188b79fa8261&pid=1-s2.0-S1359644624002538-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141887850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms 依库珠单抗对患者的疗效和安全性以及 C5 多态性的作用。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-05 DOI: 10.1016/j.drudis.2024.104134
Hendrikus Bernhard Bouwman , Henk-Jan Guchelaar
{"title":"The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms","authors":"Hendrikus Bernhard Bouwman ,&nbsp;Henk-Jan Guchelaar","doi":"10.1016/j.drudis.2024.104134","DOIUrl":"10.1016/j.drudis.2024.104134","url":null,"abstract":"<div><p>Eculizumab is an orphan drug with indications for extremely rare autoimmune disorders. It is primarily prescribed for use in patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; but is also highly effective in the treatment of myasthenia gravis, among others. By binding to the C5 protein in the complement system, eculizumab effectively inhibits cellular hemolysis and autoimmune reactions. Despite this effective treatment, some patients reported no improvement in symptoms. Genetic sequencing revealed three distinct C5 mutations in the non-responders and these polymorphisms appeared to be most prevalent among Japanese, Korean and African populations. Here, we present an overview of the current and potential future applications of eculizumab, as well as the disadvantages of eculizumab treatment in patients with C5 polymorphisms.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104134"},"PeriodicalIF":6.5,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002599/pdfft?md5=562239e012e6ef06aa266141b8daa288&pid=1-s2.0-S1359644624002599-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxygen-generating biomaterials for cardiovascular engineering: unveiling future discoveries 用于心血管工程的制氧生物材料：揭开未来发现的神秘面纱。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-03 DOI: 10.1016/j.drudis.2024.104135
Masoud Mozafari , Mohammad E. Barbati
{"title":"Oxygen-generating biomaterials for cardiovascular engineering: unveiling future discoveries","authors":"Masoud Mozafari ,&nbsp;Mohammad E. Barbati","doi":"10.1016/j.drudis.2024.104135","DOIUrl":"10.1016/j.drudis.2024.104135","url":null,"abstract":"<div><p>Oxygen-generating biomaterials are emerging as a groundbreaking solution for transforming cardiovascular engineering. These biomaterials generate and release oxygen within various biomedical applications, marking a new frontier in healthcare. Most cardiovascular treatments face a significant challenge, ensuring a consistent oxygen supply to nurture engineered tissues or even implanted devices. Traditional methods relying on passive oxygen diffusion often fall short, hindering functional cardiovascular tissue development. Oxygen-generating biomaterials, incorporating agents like calcium peroxide, provide a controlled oxygen source to the surrounding cells. This innovation potentially enhances cell viability, stimulates growth and boosts metabolic activity crucial for tissue health. Applications include repairing cardiac and vascular tissues, disease modeling, drug testing and personalized medicine, promising tailored treatments. Challenges like material toxicity and oxygen release control need consideration. As research progresses, the use of these innovative biomaterials in clinical translation could reshape cardiovascular healthcare, revolutionizing patient outcomes in heart disease treatment.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104135"},"PeriodicalIF":6.5,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002605/pdfft?md5=03c192c5e98046ed19373c8728b6f9f9&pid=1-s2.0-S1359644624002605-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in structure-based drug design targeting membrane protein markers in prostate cancer 针对前列腺癌膜蛋白标记物的结构药物设计进展。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-03 DOI: 10.1016/j.drudis.2024.104130
João P. Batista-Silva , Diana Gomes , Sérgio F. Sousa , Ângela Sousa , Luís A. Passarinha
{"title":"Advances in structure-based drug design targeting membrane protein markers in prostate cancer","authors":"João P. Batista-Silva ,&nbsp;Diana Gomes ,&nbsp;Sérgio F. Sousa ,&nbsp;Ângela Sousa ,&nbsp;Luís A. Passarinha","doi":"10.1016/j.drudis.2024.104130","DOIUrl":"10.1016/j.drudis.2024.104130","url":null,"abstract":"<div><p>Prostate cancer (PCa) is one of the leading cancers in men and the lack of suitable biomarkers or their modulators results in poor prognosis. Membrane proteins (MPs) have a crucial role in the development and progression of PCa and can be attractive therapeutic targets. However, experimental limitations in targeting MPs hinder effective biomarker and inhibitor discovery. To overcome this barrier, computational methods can yield structural insights and screen large libraries of compounds, accelerating lead identification and optimization. In this review, we examine current breakthroughs in computer-aided drug design (CADD), with emphasis on structure-based approaches targeting the most relevant membrane-bound PCa biomarkers.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104130"},"PeriodicalIF":6.5,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002551/pdfft?md5=3fd56d548a560002f71c6a4720003490&pid=1-s2.0-S1359644624002551-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the frontier of drug-like chemical space with cutting-edge generative AI models 用最先进的生成式人工智能模型探索类药物化学空间的前沿。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-03 DOI: 10.1016/j.drudis.2024.104133
Antonio Lavecchia
{"title":"Navigating the frontier of drug-like chemical space with cutting-edge generative AI models","authors":"Antonio Lavecchia","doi":"10.1016/j.drudis.2024.104133","DOIUrl":"10.1016/j.drudis.2024.104133","url":null,"abstract":"<div><p>Deep generative models (GMs) have transformed the exploration of drug-like chemical space (CS) by generating novel molecules through complex, nontransparent processes, bypassing direct structural similarity. This review examines five key architectures for CS exploration: recurrent neural networks (RNNs), variational autoencoders (VAEs), generative adversarial networks (GANs), normalizing flows (NF), and Transformers. It discusses molecular representation choices, training strategies for focused CS exploration, evaluation criteria for CS coverage, and related challenges. Future directions include refining models, exploring new notations, improving benchmarks, and enhancing interpretability to better understand biologically relevant molecular properties.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104133"},"PeriodicalIF":6.5,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002587/pdfft?md5=0ee815e5dbb9a06826d24ccadbf6fc05&pid=1-s2.0-S1359644624002587-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repurposing cardiac glycosides for anticancer treatment: a review of clinical studies 将强心苷重新用于抗癌治疗：临床研究综述。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-03 DOI: 10.1016/j.drudis.2024.104129
Wan Najbah Nik Nabil , Rongchen Dai , Mengfan Liu , Zhichao Xi , Hongxi Xu
{"title":"Repurposing cardiac glycosides for anticancer treatment: a review of clinical studies","authors":"Wan Najbah Nik Nabil ,&nbsp;Rongchen Dai ,&nbsp;Mengfan Liu ,&nbsp;Zhichao Xi ,&nbsp;Hongxi Xu","doi":"10.1016/j.drudis.2024.104129","DOIUrl":"10.1016/j.drudis.2024.104129","url":null,"abstract":"<div><p>Cardiac glycosides (CGs), which are traditionally used for heart disease, show promise for cancer therapy. However, there is a lack of a comprehensive review of clinical studies in this area, and so far, CGs have not been widely integrated into clinical cancer treatment. This review covers clinical studies from the past five years, highlighting the potential of CGs to reduce cancer risk, enhance chemotherapy effectiveness, mitigate chemotherapy-induced side effects and improve quality of life. Future clinical trials should personalize the dosage of CGs, integrate molecular testing and investigate immunogenic cell death induction and the potential of CGs for treating bone cancer and metastasis. Optimizing the repurposing of CGs for anticancer treatment requires consideration of specific CGs, cancer types and concurrent medications.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 10","pages":"Article 104129"},"PeriodicalIF":6.5,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141887853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multidisciplinary considerations for implementing Bayesian borrowing in basket trials 在篮子试验中实施贝叶斯借贷的多学科考虑因素。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-02 DOI: 10.1016/j.drudis.2024.104127
Kristine R. Broglio , Jenny E. Blau , Elizabeth A. Pilling , James M.S. Wason
{"title":"Multidisciplinary considerations for implementing Bayesian borrowing in basket trials","authors":"Kristine R. Broglio ,&nbsp;Jenny E. Blau ,&nbsp;Elizabeth A. Pilling ,&nbsp;James M.S. Wason","doi":"10.1016/j.drudis.2024.104127","DOIUrl":"10.1016/j.drudis.2024.104127","url":null,"abstract":"<div><p>Drug development has historically relied on phase I–III clinical trials including participants sharing the same disease. However, drug development has evolved as the discovery of mechanistic drivers of disease demonstrated that the same therapeutic target may provide benefits across different diseases. A basket trial condenses evaluation of one therapy among multiple related diseases into a single trial and presents an opportunity to borrow information across them rather than viewing each in isolation. Borrowing is a statistical tool but requires a foundation of clinical and therapeutic mechanistic justification. We review the Bayesian borrowing approach, including its assumptions, and provide a framework for how this approach can be evaluated for successful use in a basket trial for drug development.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104127"},"PeriodicalIF":6.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141887852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An overview of the development of pharmacotherapeutics targeting SARS-CoV-2 针对 SARS-CoV-2 的药物疗法开发概述。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-02 DOI: 10.1016/j.drudis.2024.104126
Tom Lucaj , Ian Hay , Amirreza Samarbakhsh , Mel Bedi , Arun K. Iyer , Navnath S. Gavande
{"title":"An overview of the development of pharmacotherapeutics targeting SARS-CoV-2","authors":"Tom Lucaj ,&nbsp;Ian Hay ,&nbsp;Amirreza Samarbakhsh ,&nbsp;Mel Bedi ,&nbsp;Arun K. Iyer ,&nbsp;Navnath S. Gavande","doi":"10.1016/j.drudis.2024.104126","DOIUrl":"10.1016/j.drudis.2024.104126","url":null,"abstract":"<div><p>Coronavirus disease 2019 (COVID-19) was declared a global pandemic in March 2020, which precipitated urgent public health responses. The causative agent, SARS-CoV-2, spreads primarily via respiratory droplets, necessitating precautions to mitigate transmission risks. Biopharmaceutical industries and academic institutions worldwide swiftly redirected their research endeavors towards developing therapeutic interventions, focusing on monoclonal antibodies, antiviral agents, and immunomodulatory therapies. The evolving body of evidence surrounding these treatments has prompted successive updates and revisions from the FDA, delineating the evolving landscape of COVID-19 therapeutics. This review comprehensively examines each treatment modality within the context of their developmental trajectories and regulatory approvals throughout the pandemic. Furthermore, it elucidates their mechanisms of action and presents clinical data underpinning their utility in combating the COVID-19 crisis.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104126"},"PeriodicalIF":6.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141887849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering immune responses: a comparative analysis of influenza vaccination platforms 解读免疫反应：流感疫苗接种平台的比较分析。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-08-02 DOI: 10.1016/j.drudis.2024.104125
Charles H. Jones, Teresa Hauguel, Marie Beitelshees, Michelle Davitt, Verna Welch, Kelly Lindert, Pirada Allen, Jane M. True, Mikael Dolsten
{"title":"Deciphering immune responses: a comparative analysis of influenza vaccination platforms","authors":"Charles H. Jones,&nbsp;Teresa Hauguel,&nbsp;Marie Beitelshees,&nbsp;Michelle Davitt,&nbsp;Verna Welch,&nbsp;Kelly Lindert,&nbsp;Pirada Allen,&nbsp;Jane M. True,&nbsp;Mikael Dolsten","doi":"10.1016/j.drudis.2024.104125","DOIUrl":"10.1016/j.drudis.2024.104125","url":null,"abstract":"<div><p>Influenza still poses a significant challenge due to its high mutation rates and the low effectiveness of traditional vaccines. At present, antibodies that neutralize the highly variable hemagglutinin antigen are a major driver of the observed variable protection. To decipher how influenza vaccines can be improved, an analysis of licensed vaccine platforms was conducted, contrasting the strengths and limitations of their different mechanisms of protection. Through this review, it is evident that these vaccines do not elicit the robust cellular immune response critical for protecting high-risk groups. Emerging platforms, such as RNA vaccines, that induce robust cellular responses that may be additive to the recognized mechanism of protection through hemagglutinin inhibition may overcome these constraints to provide broader, protective immunity. By combining both humoral and cellular responses, such platforms could help guide the future influenza vaccine development.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104125"},"PeriodicalIF":6.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002502/pdfft?md5=3e399cb0263bb20885a92f46d326ccaa&pid=1-s2.0-S1359644624002502-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141887851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信